Viatris Q3 Revenue $3.75B, Net Loss $325M; Raises 2026 Guidance Midpoints
VTRS sits 95% above its 52-week low of $9.92.
Summary
Viatris posted flat Q3 revenue of $3.75 billion but grew adjusted EBITDA 4% to $1.20 billion and raised 2026 guidance midpoints across all metrics, while flagging a ~$100 million Q4 revenue hit from the Nashik manufacturing suspension.
Key Events · Earnings and Guidance · VTRS
-
Q3 Revenue Flat, Adjusted EBITDA Up 4%
Total revenues were $3,749.5 million versus $3,759.9 million a year ago, while adjusted EBITDA rose to $1,195.7 million and adjusted EPS to $0.71 from $0.67.
-
2026 Guidance Midpoints Raised Across All Metrics
Revenue midpoint moves to $14,800 million from $14,750 million, adjusted EBITDA to $4,500 million from $4,400 million, adjusted EPS to $2.60 from $2.52 and free cash flow to $2,300 million from $2,200 million.
-
Nashik Facility Suspension Hits Revenue
The FDA classified the Nashik oral solid dose plant as Official Action Indicated; Viatris voluntarily suspended manufacturing in October and expects ~$100 million of Q4 revenue impact, with production resuming in Q1 2027.
-
GAAP Loss Driven by Tax Provision
The $325.3 million GAAP net loss includes a $453.2 million income tax provision tied to losses in jurisdictions where minimal benefit can be realized.
Analysis · VTRS · Life Sciences
Revenue was essentially flat year over year at $3.75 billion, but adjusted EBITDA rose 4% to $1.20 billion and adjusted EPS climbed 6% to $0.71, enough for management to lift the midpoint of every 2026 metric — revenue to $14.8 billion, adjusted EBITDA to $4.5 billion, adjusted EPS to $2.60 and free cash flow to $2.3 billion. The GAAP net loss of $325 million stems largely from a $453 million income tax provision on losses in jurisdictions where little benefit can be realized, not from operations. Against that, the Nashik facility received an FDA Official Action Indicated classification and manufacturing was voluntarily suspended in October, with roughly $100 million of revenue already lost in Q3 and another $100 million expected in Q4 before production resumes in Q1 2027. The Pacira deal remains on track to close by end of November.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VTRS was trading at $19.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.1B. The 52-week trading range was $9.92 to $19.51. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.